When do you prefer commodities over equities?

The onslaught of supply concerns and increasing demand drives the commodity prices. Increasing inflation favours exposure to commodities as opposed to equities.

What exchange platform do this product cover for commodities trading?

This product covers commodities trading on COMEX, LME, NYMEX, ICE and CBOT.

What is the time frame for this report?

Being a technical analysis report, the recommendation is provided for a short-term view.

What Are Brokers’ Price Targets for Chrysos Corporation (ASX:C79)?

Sonal Goyal

09 October 2026 11:39 AM AEDT

What Are Brokers’ Price Targets for Chrysos Corporation (ASX:C79)?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Consensus rating of Buy from 7 analysts: 7 Buy or equivalent, 0 Hold, 0 Sell or equivalent.
Mean price target of A$8.96 against a share price of A$6.96 on 8 October 2026, an implied upside of 28.7%.
Analyst targets range from A$6.50 to A$10.26.
The company said it achieved the higher end of FY26 Revenue and EBITDA guidance.

Chrysos Corporation (ASX:C79) carries a consensus analyst rating of Buy. Of the 7 analyst recommendations recorded, 7 are Buy or equivalent, 0 are Hold and 0 are Sell or equivalent. The mean price target is A$8.96, with targets ranging from A$6.50 to A$10.26, against a current share price of A$6.96 (8 October 2026). Chrysos Corporation Limited provides PhotonAssay, a technology for faster and more accurate gold analysis, through service labs and unit deployments in the Mining industry.

Company name	Chrysos Corporation
Ticker	(ASX:C79)
Exchange	ASX (Australian Securities Exchange)
Current share price	A$6.96
Price date	8 October 2026
Number of analysts	7
Rating consensus	Buy
Consensus price target (mean)	A$8.96
Highest target	A$10.26
Lowest target	A$6.50
Implied upside/downside to mean target	Implied upside of 28.7%

Latest developments

Chrysos Corporation (ASX:C79) presented its FY26 financial results on 11 August 2026. The company said it achieved the higher end of FY26 revenue and EBITDA guidance. Total revenue was $88.1 million, made up of MMAP revenue of $62.5 million, up 12%, and AAC revenue of $25.5 million, up 153%. AAC represented 29% of revenue, up from 15% in FY25. The EBITDA Margin was 31%, compared with 24% in FY25.

The company reported an operating cash inflow of $17.9 million, refinanced its Debt Facility arrangement and said it is funded to support an increased Manufacturing cadence of PhotonAssay units. Seven units were deployed in FY26 and six are currently deploying, bringing total contracted units to 87, including post-period leases. The group processed 11.3 million samples in FY26, up 67%, and monthly throughput surpassed a record of 1 million samples.

Quarterly PhotonAssay sample volumes grew about 2.4 times over the last 24 months, and the company noted that sample growth is outpacing fleet growth through higher utilisation, with hub labs able to support further demand, particularly in EMEA.

Sector context

The company describes continued conversion to PhotonAssay from conventional fire assay and industry activity as drivers of sample volumes, and presents PhotonAssay as a faster and more accurate analysis method for the gold sector. Demand for its services therefore relates to mining and exploration activity.

Risks and what to watch

Revenue depends on sample volumes and unit deployments, which relate to mining and exploration activity. Total contracted units of 87 include post-period leases, and the deployment of six units is still in progress. The company is increasing its manufacturing cadence, which requires capital. FY27 guidance is set out in the company's materials.

Next milestones

Items to watch include deployment of the six units currently deploying, sample volumes and utilisation, AAC growth, FY27 guidance delivery, and the company's half-year result.

FAQs

Q: What is the consensus analyst rating for Chrysos Corporation (ASX:C79)?

A:The consensus rating is Buy, based on 7 analyst recommendations: 7 Buy or equivalent, 0 Hold and 0 Sell or equivalent.

Q: What are the analyst price targets for Chrysos Corporation (ASX:C79)?

A:The mean price target is A$8.96, with a highest target of A$10.26 and a lowest target of A$6.50. The share price on 8 October 2026 was A$6.96.

Q: What did Chrysos (ASX:C79) report for FY26?

A:Chrysos reported revenue of $88.1 million, an EBITDA margin of 31%, operating cash inflow of $17.9 million, 11.3 million samples processed and 87 total contracted units.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.